Table 3.
Univariate and multivariate analysis of survival without treatment failure
| Variable | Univariate analysis (HR [CI95]) | p-value | Multivariate analysis (aHR [CI95]) | p-value |
|---|---|---|---|---|
| Sexe | ||||
|
Female Male |
1 1.15 [0.44–2.99] |
- 0.770 |
- | - |
| Active neoplasia | ||||
|
No Yes |
1 3.30 [1.27–8.60] |
- 0.014 |
1 4.12 [1.22-13.847] |
- 0.022 |
| Intensive care unit admission | ||||
|
No Yes |
1 1.46 [0.54–3.97] |
- 0.451 |
1 2.6 [0.86–3.02] |
- 0.091 |
| Age | ||||
| + 10 years | 1.16 [0.79–1.71] | 0.450 | - | - |
| Charlson score | ||||
|
< 2 ≥ 2 |
1 1.40 [0.46–4.30] |
- 0.556 |
1 0.85 [0.24–3.02] |
- 0.807 |
| Anti-staphylococcal treatment | ||||
|
Linezolid Vancomycin |
1 3.18 [1.03–9.79] |
- 0.043 |
1 2.94 [0.93–9.30] |
- 0.066 |
| Bloodstream infection associated | ||||
|
No Yes |
1 1.25 [0.41–3.85] |
- 0.692 |
- | - |
| Type on infection | ||||
|
Deep-brain stimulator infection Meningitis Empyema and/or abscess |
1 0.68 [0.09–5.325] 1.70 [0.20–14.2] |
- 0.714 0.622 |
- | - |
| Methicillin resistance | ||||
|
No Yes |
1 0.63 [0.23–1.70] |
- 0.363 |
- | - |
| Staphylococcus species | ||||
|
Coagulase-negative staphylococci S. aureus |
1 2.58 [0.99–6.70] |
- 0.051 |
1 2.19 [0.80–5.98] |
- 0.127 |
| Combination therapy with β-lactam | ||||
|
No Yes |
1 1.11 [0.42–2.91] |
- 0.834 |
- | - |
| Implant/devices removal A | ||||
|
No Yes |
1 0.43 [0.12–1.58] |
- 0.201 |
- | - |
HR: Hazard ratio; aHR: adjusted Hazard ratio; CI: confidence interval A: Among patient with implant (n = 68)